论文部分内容阅读
目的探讨重组人生长激素（ｒｈＧＨ）对青春期前特发性生长激素缺乏症（ＩＧＨＤ）患者的疗效。方法对３家医院的６３例ＩＧＨＤ以ｒｈＧＨ进行治疗，每晚临睡前皮下注射０．１ＩＵ／ｋｇ共６个月。结果６３例患儿身高平均增加（７．０±１．６）厘米，年生长速度由治疗前的（２．９±０．９）厘米／年，增加到（１４．０±３．２）厘米／年，身高标准差计分（ＳＤＳ）由治疗前的（－４．８±１．７）变为（－３．９±１．６）；体重也明显增加，但对骨龄无明显促进作用。治疗期间有３９．７％的患儿出现亚临床甲状腺功能低减，２２．４％的患儿于注射局部曾出现短暂的红肿或痒等，７．９％的患儿出现血清ＡＬＴ轻度升高，但所有这些现象均未影响患儿体格的线性增长。结论ｒｈＧＨ是治疗ＩＧＨＤ的一种安全、有效的促生长药物。
Objective To investigate the effect of recombinant human growth hormone (rhGH) on pre-puberty patients with idiopathic growth hormone deficiency (IGHD). Methods Sixty-three IGHD patients in three hospitals were treated with rhGH. Subcutaneous injection of 0.1 IU / kg for 6 months before going to sleep every night. Results The average height of the 63 children (7.0 ± 1.6) cm increased from (2.9 ± 0.9) cm / year before treatment to (14.0 ± 3.2) Cm / year, the standard deviation score (SDS) from pre-treatment (-4.8 ± 1.7) to (-3.9 ± 1.6); body weight also increased significantly, but no significant increase in bone age effect. Subclinical hypothyroidism occurred in 39.7% of the patients during the treatment period, and transient redness or itching appeared in 22.4% of the patients. 7.9% of the patients had slight increase of serum ALT High, but all these phenomena did not affect the physical growth of children with linear. Conclusion rhGH is a safe and effective growth-promoting drug for the treatment of IGHD.